Evogene (NASDAQ: EVGN) reported Q1 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $3.38 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.